UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Use of Pharmacokinetic-Pharmacodynamic Analyses To Optimize Therapy with the Systemic Antifungal Micafungin for Invasive Candidiasis or Candidemia

Antimicrobial Agents and Chemotherapy, 2011-05, Vol.55 (5), p.2113-2121

2011

Volltextzugriff (PDF)

Randomized Pharmacokinetic and Pharmacodynamic Comparison of Fluoroquinolones for Tuberculous Meningitis

Antimicrobial Agents and Chemotherapy, 2011-07, Vol.55 (7), p.3244-3253

2011

Volltextzugriff (PDF)

Safety and pharmacokinetics of docetaxel in combination with pegvorhyaluronidase alfa in patients with non‐small cell lung cancer

Clinical and translational science, 2021-09, Vol.14 (5), p.1875-1885

2021

Volltextzugriff (PDF)

Clinical Pharmacodynamic Index Identification for Micafungin in Esophageal Candidiasis: Dosing Strategy Optimization

Antimicrobial Agents and Chemotherapy, 2013-11, Vol.57 (11), p.5714-5716

2013

Volltextzugriff (PDF)

Oritavancin Population Pharmacokinetics in Healthy Subjects and Patients with Complicated Skin and Skin Structure Infections or Bacteremia

Antimicrobial Agents and Chemotherapy, 2009-10, Vol.53 (10), p.4422-4428

2009

Volltextzugriff (PDF)

Pharmacokinetic-Pharmacodynamic Target Attainment Analyses To Evaluate In Vitro Susceptibility Test Interpretive Criteria for Ceftaroline against Staphylococcus aureus and Streptococcus pneumoniae

Antimicrobial Agents and Chemotherapy, 2014-02, Vol.58 (2), p.885-891

2014

Volltextzugriff (PDF)

Population Pharmacokinetics of Oseltamivir: Pediatrics through Geriatrics

Antimicrobial Agents and Chemotherapy, 2013-08, Vol.57 (8), p.3470-3477

2013

Volltextzugriff (PDF)

Pharmacokinetic–pharmacodynamic modeling to support doripenem dose regimen optimization for critically ill patients

Diagnostic microbiology and infectious disease, 2009-04, Vol.63 (4), p.409-414

2009

Volltextzugriff (PDF)

Pharmacokinetic-Pharmacodynamic Analyses for Efficacy of Ceftaroline Fosamil in Patients with Community-Acquired Bacterial Pneumonia

Antimicrobial Agents and Chemotherapy, 2013-12, Vol.57 (12), p.6348-6350

2013

Volltextzugriff (PDF)

Population Pharmacokinetic Analyses for Omadacycline Using Phase 1 and 3 Data

Antimicrobial agents and chemotherapy, 2020-06, Vol.64 (7)

2020

Volltextzugriff (PDF)

Population Pharmacokinetic Analyses for Plazomicin Using Pooled Data from Phase 1, 2, and 3 Clinical Studies

Antimicrobial agents and chemotherapy, 2019-04, Vol.63 (4)

2019

Volltextzugriff (PDF)

Defining the impact of severity of illness on time above the MIC threshold for cefepime in Gram-negative bacteraemia: a ‘Goldilocks’ window

International journal of antimicrobial agents, 2017-09, Vol.50 (3), p.487-490

2017

Volltextzugriff (PDF)

Use of a clinically derived exposure–response relationship to evaluate potential tigecycline-Enterobacteriaceae susceptibility breakpoints

Diagnostic microbiology and infectious disease, 2009-01, Vol.63 (1), p.38-42

2009

Volltextzugriff (PDF)

Mathematical modeling of herpes simplex virus-2 suppression with pritelivir predicts trial outcomes

Science translational medicine, 2016-02, Vol.8 (324), p.324ra15

2016

Volltextzugriff (PDF)

Population pharmacokinetics of ceftaroline in patients with acute bacterial skin and skin structure infections or community-acquired bacterial pneumonia

Journal of clinical pharmacology, 2013-11, Vol.53 (11), p.1155-1167

2013

Volltextzugriff (PDF)

Pharmacokinetic-pharmacodynamic analysis for efficacy of ceftaroline fosamil in patients with acute bacterial skin and skin structure infections

Antimicrobial agents and chemotherapy, 2015-01, Vol.59 (1), p.372-380

2015

Volltextzugriff (PDF)

PK–PD Compass: bringing infectious diseases pharmacometrics to the patient’s bedside

Journal of pharmacokinetics and pharmacodynamics, 2017-04, Vol.44 (2), p.161-177

2017

Volltextzugriff (PDF)

Population-based meta-analysis of furosemide pharmacokinetics

Biopharmaceutics & drug disposition, 2014-03, Vol.35 (2), p.119-133

2014

Volltextzugriff (PDF)

Population-based meta-analysis of hydrochlorothiazide pharmacokinetics

Biopharmaceutics & drug disposition, 2013-12, Vol.34 (9), p.527-539

2013

Volltextzugriff (PDF)

1388. Dose Discrimination for ASN100: Bridging from Rabbit Survival Data to Predicted Activity in Humans Using a Minimal Physiologically Based Pharmacokinetic (mPBPK) Model

Open forum infectious diseases, 2018-11, Vol.5 (suppl_1), p.S426-S426

2018

Volltextzugriff (PDF)

Correction to: PK–PD Compass: bringing infectious diseases pharmacometrics to the patient’s bedside

Journal of pharmacokinetics and pharmacodynamics, 2018-04, Vol.45 (2), p.351-351

2018

Volltextzugriff (PDF)

Population pharmacokinetics of tolvaptan in healthy subjects and patients with hyponatremia secondary to congestive heart failure or hepatic cirrhosis

Biopharmaceutics & drug disposition, 2013-09, Vol.34 (6), p.336-347

2013

Volltextzugriff (PDF)

Application of patient population-derived pharmacokinetic–pharmacodynamic relationships to tigecycline breakpoint determination for staphylococci and streptococci

Diagnostic microbiology and infectious disease, 2009-02, Vol.63 (2), p.155-159

2009

Volltextzugriff (PDF)

Population Pharmacokinetic-Pharmacodynamic Modeling of Neutrophil and Platelet Count for Lower-Intensity Therapy of CPX-351 Combined with Venetoclax in Acute Myeloid Leukemia

Blood, 2023-11, Vol.142 (Supplement 1), p.2902-2902

2023

Volltextzugriff (PDF)

Population Pharmacokinetic (PK)/Pharmacodynamic (PD) Modeling of Myelosuppression in Patients with Hematologic Malignancies for CPX-351 and Standard-of-Care 7+3 Therapy

Blood, 2018-11, Vol.132 (Supplement 1), p.4037-4037

2018

Volltextzugriff (PDF)

1 – 25 von 51

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(49)
Mit Volltextzugriff
(46)

Publikationsform

Sprache

Englisch
(51)

Erscheinungsjahr

n.n

Thema

Science & Technology
(33)
Life Sciences & Biomedicine
(32)
Humans
(28)
Pharmacology & Pharmacy
(24)
Male
(22)
Female
(21)
Microbiology
(19)
Middle Aged
(18)
Adult
(15)
Biological And Medical Sciences
(15)
Medical Sciences
(15)
Anti-Bacterial Agents - Pharmacokinetics
(13)
Aged
(12)
Models, Biological
(11)
Pharmacokinetics
(11)
Pharmacology. Drug Treatments
(11)
Young Adult
(10)
Anti-Bacterial Agents
(9)
Infectious Diseases
(9)
Pharmacology
(9)

15 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Use of Pharmacokinetic-Pharmacodynamic Analyses To Optimize Therapy with the Systemic Antifungal Micafungin for Invasive Candidiasis or Candidemia

Randomized Pharmacokinetic and Pharmacodynamic Comparison of Fluoroquinolones for Tuberculous Meningitis

Safety and pharmacokinetics of docetaxel in combination with pegvorhyaluronidase alfa in patients with non‐small cell lung cancer

Clinical Pharmacodynamic Index Identification for Micafungin in Esophageal Candidiasis: Dosing Strategy Optimization

Oritavancin Population Pharmacokinetics in Healthy Subjects and Patients with Complicated Skin and Skin Structure Infections or Bacteremia

Pharmacokinetic-Pharmacodynamic Target Attainment Analyses To Evaluate In Vitro Susceptibility Test Interpretive Criteria for Ceftaroline against Staphylococcus aureus and Streptococcus pneumoniae

Population Pharmacokinetics of Oseltamivir: Pediatrics through Geriatrics

Pharmacokinetic–pharmacodynamic modeling to support doripenem dose regimen optimization for critically ill patients

Pharmacokinetic-Pharmacodynamic Analyses for Efficacy of Ceftaroline Fosamil in Patients with Community-Acquired Bacterial Pneumonia

Population Pharmacokinetic Analyses for Omadacycline Using Phase 1 and 3 Data

Population Pharmacokinetic Analyses for Plazomicin Using Pooled Data from Phase 1, 2, and 3 Clinical Studies

Defining the impact of severity of illness on time above the MIC threshold for cefepime in Gram-negative bacteraemia: a ‘Goldilocks’ window

Use of a clinically derived exposure–response relationship to evaluate potential tigecycline-Enterobacteriaceae susceptibility breakpoints

Mathematical modeling of herpes simplex virus-2 suppression with pritelivir predicts trial outcomes

Population pharmacokinetics of ceftaroline in patients with acute bacterial skin and skin structure infections or community-acquired bacterial pneumonia

Pharmacokinetic-pharmacodynamic analysis for efficacy of ceftaroline fosamil in patients with acute bacterial skin and skin structure infections

PK–PD Compass: bringing infectious diseases pharmacometrics to the patient’s bedside

Population-based meta-analysis of furosemide pharmacokinetics

Population-based meta-analysis of hydrochlorothiazide pharmacokinetics

1388. Dose Discrimination for ASN100: Bridging from Rabbit Survival Data to Predicted Activity in Humans Using a Minimal Physiologically Based Pharmacokinetic (mPBPK) Model

Correction to: PK–PD Compass: bringing infectious diseases pharmacometrics to the patient’s bedside

Population pharmacokinetics of tolvaptan in healthy subjects and patients with hyponatremia secondary to congestive heart failure or hepatic cirrhosis

Application of patient population-derived pharmacokinetic–pharmacodynamic relationships to tigecycline breakpoint determination for staphylococci and streptococci

Population Pharmacokinetic-Pharmacodynamic Modeling of Neutrophil and Platelet Count for Lower-Intensity Therapy of CPX-351 Combined with Venetoclax in Acute Myeloid Leukemia

Population Pharmacokinetic (PK)/Pharmacodynamic (PD) Modeling of Myelosuppression in Patients with Hematologic Malignancies for CPX-351 and Standard-of-Care 7+3 Therapy

Suchergebnisse filtern